Wegovy vs Ozempic in the UK

At a glance

Why two products for the same drug

Novo Nordisk developed semaglutide first as Ozempic for type 2 diabetes (UK licence 2018). The same active ingredient was then developed at higher doses for chronic weight management; the STEP trial programme established the case for the 2.4 mg dose. Wegovy is the brand for that weight-management indication.

Each indication required its own regulatory submission, trial programme, and clinical-trial dossier. Separating into two brands lets Novo Nordisk price, supply, and market each product separately — important because diabetes prescribing (single-payer-dominated, price-sensitive) and weight-management prescribing (mixed payer, often private) are commercially different markets.

The off-label problem

During Wegovy supply shortages and waiting-list pressure, clinicians have prescribed Ozempic off-label for weight management. This is lawful where the GMC-registered prescriber takes documented personal clinical responsibility, but it has caused real problems:

• Sustained pressure on Ozempic supply for diabetes patients — the licensed indication.
• Inability to achieve the 2.4 mg dose (Ozempic max is 2 mg) that Wegovy trials used to establish efficacy.
• MHRA and prescribing-body guidance asking clinicians to prioritise Ozempic for T2DM and direct weight-management patients to Wegovy or Mounjaro.

What this means for a patient

• If you have a Wegovy prescription, it can’t be filled with Ozempic at the pharmacy.
• If you have an Ozempic prescription for weight management, ask your prescriber whether transition to Wegovy or Mounjaro is appropriate — that’s now the conventional pathway.
• If you have an Ozempic prescription for type 2 diabetes, don’t worry — the licensed indication is yours and supply guidance favours diabetes patients.
• Don’t go grey-market because of a supply gap. See GLP-1 shortages for the safer alternatives.